A monopoly-grade cataract innovation with ~80% gross margins—and a broken go-to-market—trading near its cash floor as investors wager on a utilization turnaround or strategic takeout.
Overview
RxSight is a small-cap ophthalmic medtech with arguably the most disruptive cataract innovation in a decade: the Light Adjustable Lens, the only commercially available IOL that can be adjusted after surgery to eliminate refractive surprises and deliver customized vision. Despite this technical leadership, shares have collapsed to ~$10.79 from ~$64 (May 2024) after 2025 exposed a mismatch between clinical excellence and commercial scalability. The company’s early “land grab” strategy—driven by selling expensive Light Delivery Devices—hit saturation faster than expected, driving a sharp slowdown from +57% growth in 2024 to an estimated -7% to -11% contraction in 2025. Importantly, the economic engine underneath improved: as high-margin consumable LAL revenue became a larger mix, corporate gross margins expanded to ~80%. Heading into 2026, the thesis pivots to “utilization over expansion”: monetizing an installed base of ~1,109 devices by increasing procedure volume per account. This is execution-heavy and occurs amid intensifying competition from Alcon and J&J’s efficiency-friendly premium lenses and potential 2026 CMS reimbursement cuts. Valuation appears to price in distress (EV ~ $241M, <2x trailing revenue) despite a fortress balance sheet (~$227.5M cash, no debt). The report frames RXST as a high-risk asymmetric opportunity—part operational turnaround, part strategic M&A call option.